XML 59 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Accounting and Reporting Policies (Policies)
9 Months Ended
Sep. 30, 2013
Accounting Policies [Abstract]  
Basis of presentation
(a) Basis of presentation
 
The accompanying consolidated financial statements include the accounts of the Legal Parent, I/P and their wholly-owned subsidiaries, and are presented in accordance with instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with generally accepted accounting principles. These financial statements should be read in conjunction with the consolidated financial statements and related notes for the year ended December 31, 2012 included in the Company's Annual Report on Form 10-K. The results of operations for the three and nine month periods ended September 30, 2013 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. All significant intercompany balances and transactions have been eliminated in consolidation.
Development stage enterprise
(b) Development stage enterprise
 
The Company’s principal activities to date have been focused on development and enforcement of its intellectual property, and on the research and development of its products. To date, the Company has not generated significant revenues from its principal operations. Accordingly, the Company’s financial statements are presented as those of a development stage enterprise.
Translation into U.S. dollars
(c) Translation into U.S. dollars
 
  The Company conducts significant transactions in foreign currencies, which are recorded at the exchange rate as of the transaction date. All exchange gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected as non-operating income or expense in the statement of operations, as they arise.
Use of estimates
(d) Use of estimates
 
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as at the date of the financial statements and the reported amounts of revenues and expenses during the reported periods. Actual results may differ from such estimates. Significant items subject to such estimates and assumptions include valuation of assets acquired and liabilities assumed as part of the Merger, useful lives of the Company’s tangible and intangible assets, valuation of its October 2012 Warrants and derivative warrants, valuation of stock-based compensation, deferred tax assets and liabilities, income tax uncertainties and other contingencies.
Cash and cash equivalents
(e) Cash and cash equivalents
 
The Company invests its cash in commercial paper, money market deposits and money market funds with financial institutions. The Company has established guidelines relating to diversification and maturities of its investments, in order to minimize credit risk and maintain high liquidity of funds. All highly liquid investments with original maturities of three months or less are considered cash equivalents.
Revenue recognition
(f) Revenue recognition
 
Revenue from patent licensing and enforcement, subscription services and software development is recognized if collection is probable, persuasive evidence of an arrangement exists, the sales price is fixed or determinable and delivery of the service has been rendered. The Company uses management's best estimate of selling price for individual elements in multiple-element arrangements, where other sources of evidence are unavailable.
Cost of revenue
(g) Cost of revenue
 
Cost of revenue mainly includes expenses incurred in connection with the Company’s patent enforcement activities, such as legal fees, consulting costs, patent maintenance and other related expenses, as well as the amortization of acquired patents and technology. Legal costs incurred in connection with ongoing litigation are expensed as incurred. Cost of revenue also includes expenses directly related to providing mobile services in launched markets. In addition, these costs include royalty fees for content sales and amortization of prepaid content licenses. Cost of revenue does not include expenses related to product development, integration or support, as these are included in research and development expenses.
Net loss per share data
(h) Net loss per share data
 
Basic net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss for the period by the weighted-average number of shares of common stock plus dilutive potential common stock considered outstanding during the period. Such dilutive shares consist of incremental shares that would be issued upon exercise of the Company’s derivative warrants. The table below presents the computation of basic and diluted net losses per common share for the periods presented:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cumulative
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
from Inception
 
 
 
Three months ended September 30,
 
Nine months ended September 30,
 
to September 30,
 
 
 
2013
 
2012
 
2013
 
2012
 
2013
 
Basic Numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to shares of common stock
 
$
(10,560)
 
$
(3,124)
 
$
(33,464)
 
$
(6,836)
 
$
(57,059)
 
Basic Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted average number of shares of common stock outstanding during the period
 
 
83,450,697
 
 
48,437,587
 
 
82,757,899
 
 
25,493,415
 
 
46,229,656
 
Weighted average number of penny stock options
 
 
88,070
 
 
353,232
 
 
124,506
 
 
117,744
 
 
109,930
 
Basic common stock shares outstanding
 
 
83,538,767
 
 
48,790,819
 
 
82,882,405
 
 
25,611,159
 
 
46,339,586
 
Basic net loss per common stock share
 
$
(0.13)
 
$
(0.06)
 
$
(0.40)
 
$
(0.27)
 
$
(1.23)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Numerator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss attributable to shares of common stock
 
$
(10,560)
 
$
(3,124)
 
$
(33,464)
 
$
(6,836)
 
$
(57,059)
 
Increase in net loss attributable to derivative warrants
 
 
(758)
 
$
(7,240)
 
$
(53)
 
$
(7,240)
 
$
(3,387)
 
Diluted net loss attributable to shares of common stock:
 
$
(11,318)
 
$
(10,364)
 
$
(33,517)
 
$
(14,076)
 
$
(60,446)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diluted Denominator:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Basic common shares outstanding
 
 
83,538,767
 
 
48,790,819
 
 
82,882,405
 
 
25,611,159
 
 
46,339,586
 
Weighted average number of derivative warrants outstanding during the period
 
 
2,563,090
 
 
9,436,281
 
 
89,677
 
 
9,436,281
 
 
1,460,477
 
Diluted common stock shares outstanding
 
 
86,101,857
 
 
58,227,100
 
 
82,972,082
 
 
35,047,440
 
 
47,800,063
 
Diluted net loss per common stock share
 
$
(0.13)
 
$
(0.18)
 
$
(0.40)
 
$
(0.40)
 
$
(1.26)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net loss per share data presented excludes from the calculation of diluted net loss the following potentially dilutive securities, as of September 30 of the applicable period, as they had an anti-dilutive impact:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both vested and unvested options at $0.96-$5.50 exercise price, to purchase an equal number of shares of common stock of the Company
 
 
10,225,387
 
 
9,160,429
 
 
10,225,387
 
 
9,160,429
 
 
10,225,387
 
Unvested penny options to purchase an equal number of shares of common stock of the Company
 
 
 
 
30,250
 
 
 
 
30,250
 
 
 
Unvested RSUs to issue an equal number of shares of common stock of the Company
 
 
2,411,771
 
 
3,126,667
 
 
2,411,771
 
 
3,126,667
 
 
2,411,771
 
Common stock shares granted, but not yet vested
 
 
45,762
 
 
108,625
 
 
45,762
 
 
108,625
 
 
45,762
 
Warrants to purchase an equal number of shares of common stock of the Company
 
 
15,829,262
 
 
12,814,533
 
 
18,289,611
 
 
12,814,533
 
 
15,115,357
 
Total number of potentially dilutive instruments, excluded from the calculation of net loss per share:
 
 
28,512,182
 
 
25,240,504
 
 
30,972,531
 
 
25,240,504
 
 
27,798,277